2024-03-29T13:32:06Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00022178
2022-12-15T03:52:31Z
453:456
471:537:538:1196
Childhood Leukemia(20th Meeting of the Niigata Society of Hematologic Neoplasm The Ten-year Anniversary Symposium : Progress in Hematologic Neoplasm over the Ten Years)
小児白血病(第20回新潟造血器腫瘍研究会十周年記念シンポジウム : 造血器腫瘍十年の歩み)
小児白血病(第20回新潟造血器腫瘍研究会十周年記念シンポジウム : 造血器腫瘍十年の歩み)
内海, 治郎
134789
浅見, 恵子
134790
笹崎, 義弘
134791
acute lymphocytic leukemia(ALL)
risk factors
cessation of maintenance therapy
92 patients with acute lymphocytic leukemia (ALL), 29 patients with acute nonlymphocytic leukemia (ANLL), and 6 patients with chronic myelogenous leukemia (CML) admitted to the Department of Pediatrics, Niigata Cancer Center Hospital between Jan. 1961 and Dec. 1988 are reviewed in this study. From 1981 to 1985, a complete remission in 96% of patients with ALL could be archived by remission induction therapies according to risk factors. The rate of continuous complete remission was 74% at 3 years and 57% at 5 years after a complete remission of the bone marrow. Cessation of maintenance therapies in 21 patients with ALL, who began remission induction therapies from 1977 to 1985 and continuous complete remission for more than 3 years, was undertaken. After cessation of therapies, the rate of continuous complete remission was 86% at 3 years and relapses were not seen for more than 3 years. Relapses occured in 4 patients from 2 to 26 months after cessation of therapies. The sites of the relapses were 3 case of bone marrow, and 1 case of bone marrow/CNS. Compared with ALL, the results of remission induction and maintenance therapies in childhood ANLL and CML are not as positive and bone marrow transplantation must be introduced in pediatrics.
departmental bulletin paper
新潟医学会
1990-07
application/pdf
新潟医学会雑誌
7
104
569
574
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/22178/files/104(7)_569-574.pdf
jpn